A Study in Subjects With Perennial Allergic Rhinitis

• Status: Completed
• Trial end date: 2003-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study was to determine the efficacy and safety of the study drug compared to placebo for the treatment of subjects with perennial allergic rhinitis.

• Phase: Phase 2

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• Have a documented history of allergy to perennial allergens and demonstrated sensitivity by the results of prick or intradermal skin testing.

• Have a self-reported history of at least mild, intermittent rhinorrhea and nasal blockage/stuffiness due to allergies.

• Have not started or had a change in immunotherapy regimen.

Exclusion Criteria:

• Have a physical obstruction in the nose.

• Will likely have an acute increase in severity of allergic rhinitis due to seasonal aeroallergens during the trial.

• Have acute or chronic sinusitis or had previous sinus surgery resulting in a significant change in the sinus or nasal anatomy.

• Have rhinitis medicamentosa or any other acute or chronic condition that could confound evaluations of nasal symptoms.

• Have asthma of sufficient severity to require use of excluded medications.

• Have taken any medications excluded as listed in the protocol.

• Have a clinically significant acute or chronic disease or clinically significant laboratory abnormality.

• Are a current smoker, recent smoker or past smoker as defined in the protocol.